Compare Regeneron Pharmaceuticals Inc (REGN) vs Zoom Video Communications, Inc. (ZM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Zoom Video Communications, Inc. — how do they compare? Regeneron Pharmaceuticals Inc trades at $745.31 (market cap $76.14B), while Zoom Video Communications, Inc. trades at $96.25 (market cap $27.62B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.8× Zoom Video Communications, Inc.'s market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Zoom Video Communications, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Zoom Video Communications, Inc. for 92 Days on average.
| REGN | ZM | |
|---|---|---|
Market Cap | $76.14B | $27.62B |
Volume | 500,239 | 3,913,188 |
Sector | Health | Technology |
52-Week High | $852.03 | $111.88 |
52-Week Low | $557.73 | $72.72 |
Typical Hold Time | 107 Days | 92 Days |
Enterprise Value | $70.85B | $20.43B |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.
The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.
Zoom Communications (ZM) trades at $94.77, up 0.61% with a bullish technical outlook. The stock shows strong profitability with 77.3% gross margins and 65.19% net income margin, supported by recent earnings beats. Analyst consensus targets $118.08 with 38.8% buy ratings. Recent AI product launches and board appointments signal strategic growth initiatives.
Zoom presents a compelling investment case with attractive valuation (P/E 8.79) and robust profitability, though near-term risks include competitive pressures and reliance on international sales. The stock's proximity to resistance at $95 requires monitoring, but institutional interest and AI-driven revenue initiatives support long-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Zoom Video Communications, Inc.
Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.
Read more on ZM →
